Form 4 for TXG 10x Genomics, Inc.
Accepted 2021-11-04 00:00:00 ET · period of report 2021-11-02 · accession 0001567619-21-019360 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-04 | 2021-11-02 | TXG | Saxonov Serge | CEO, Dir | S - Sale+OE | $161.24 | -15.0K | 891.2K | -2% | -$2.42M |
| DM | 2021-11-04 | 2021-11-02 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $7.41 | +8,245 | 900.4K | +0.9% | +$61.1K |
| DM | 2021-11-04 | 2021-11-02 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $0.00 | -8,245 | 51.6K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2021-11-02 | S | D | 5,613 | $161.94 | 885,581 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $161.63 to $162.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2021-11-02 | S | D | 200 | $163.14 | 885,381 | D | — | — | |
| 3 | Common | Class A Common Stock | 2021-11-02 | M | A | 5,208 | $5.04 | 897,344 | D | — | — | |
| 4 | Common | Class A Common Stock | 2021-11-02 | M | A | 3,037 | $11.48 | 900,381 | D | — | — | |
| 5 | Common | Class A Common Stock | 2021-11-02 | S | D | 3,241 | $160.26 | 897,140 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $159.60 to $160.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 6 | Common | Class A Common Stock | 2021-11-02 | S | D | 5,946 | $161.06 | 891,194 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $160.60 to $161.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 7 | Derivative | Stock Option (right to buy) | 2021-11-02 | M | D | 5,208 | $0.00 | 58,532 | D | $5.04 · — to 2028-11-02 | 5,208 Class A Common Stock | (F7) This option, originally for 250,000 shares, of which 191,468 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| 8 | Derivative | Stock Option (right to buy) | 2021-11-02 | M | D | 3,037 | $0.00 | 51,633 | D | $11.48 · — to 2029-05-10 | 3,037 Class A Common Stock | (F8) This option, originally for 145,786 shares, of which 94,153 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |